• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amarin Corp ADR (NQ: AMRN )

    0.5923 -0.0309 (-4.96%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Amarin Corp ADR

    < Previous 1 2 3 4 5 6 Next >
    Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Announces Two Upcoming Investor Events
    From Amarin Corporation plc
    Via GlobeNewswire
    Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
    From Amarin Corporation plc
    Via GlobeNewswire
    Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Board of Directors Announces CEO Transition
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Reports First Quarter 2024 Business Update and Financial Results
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
    Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients 
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Announces Results of Annual General Meeting of Shareholders
    - Shareholders Approve Share Repurchase Program of up to $50 Million - 
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
    Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action 
    From Amarin Corporation plc
    Via GlobeNewswire
    New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
    Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 
    From Amarin Corporation plc
    Via GlobeNewswire
    Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Chairman & CEO Issue Letter to Shareholders
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Amarin Corporation plc
    Via GlobeNewswire
    New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Reports Third Quarter 2023 Financial Results
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
    From Amarin Corporation plc
    Via GlobeNewswire
    Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
    -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- 
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Present at the 2023 Cantor Global Healthcare Conference
    From Amarin Corporation plc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.